Newer Is Better In Implant For Prostate Cancer
A study by Yale
University researchers in New Haven, Conn., shows a newer radiation implant
therapy has fewer side effects and could lead to better treatment outcomes
than the older, more commonly prescribed treatment.
The new treatment, Palladium-103, was compared with the more traditional
Iodine-125 in the study.
"While both implants were extraordinarily successful at preventing major
long-term complications, Palladium-103 was superior to Iodine-125 in
preventing moderate long-term complications by 13 percent," said Dr. Richard
Peschel, professor of therapeutic radiology at Yale School of Medicine.
"Our study is the first to compare prostate cancer implant therapies, and
the results could lead to improved outcomes for patients."
In the seven-year study, Peschel and his team also found that the minimum
dose for Palladium-103 could be increased without increasing side effects.
This increased dose has the potential for improving cure rates, Peschel
said in the journal Radiation Oncology Investigations: Clinical and Basic